These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2679288)

  • 1. Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials.
    Fisher B; Redmond C; Wickerham DL; Wolmark N; Bowman D; Couture J; Dimitrov NV; Margolese R; Legault-Poisson S; Robidoux A
    Ann Intern Med; 1989 Nov; 111(9):703-12. PubMed ID: 2679288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project.
    Fisher B; Redmond C
    J Natl Cancer Inst Monogr; 1992; (11):105-16. PubMed ID: 1627417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
    Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
    J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
    J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
    Land SR; Kopec JA; Yothers G; Anderson S; Day R; Tang G; Ganz PA; Fisher B; Wolmark N
    Breast Cancer Res Treat; 2004 Jul; 86(2):153-64. PubMed ID: 15319567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.
    Fisher B; Redmond C; Dimitrov NV; Bowman D; Legault-Poisson S; Wickerham DL; Wolmark N; Fisher ER; Margolese R; Sutherland C
    N Engl J Med; 1989 Feb; 320(8):473-8. PubMed ID: 2644531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
    Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
    J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial.
    Fisher B; Brown A; Wolmark N; Redmond C; Wickerham DL; Wittliff J; Dimitrov N; Legault-Poisson S; Schipper H; Prager D
    Ann Intern Med; 1987 May; 106(5):649-54. PubMed ID: 3551710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.
    Fisher B; Redmond C; Brown A; Fisher ER; Wolmark N; Bowman D; Plotkin D; Wolter J; Bornstein R; Legault-Poisson S
    J Clin Oncol; 1986 Apr; 4(4):459-71. PubMed ID: 2856857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
    Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
    J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
    J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
    Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
    J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
    J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.